The U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.
It's a decision that immediately affects CBD producers but also signals the agency’s first admission that the plant has medical value.
DEA moves CBD medicines off Schedule 1, a limited expansion of cannabis access is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs